Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2c

Note: EPS may not be comparable

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.56), $0.02 worse than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
• Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance